Loading…

Phosphaturic mesenchymal tumor: Case report

Phosphaturic mesenchymal tumors (PMT) are an extremely rare pathologic phenomenon that presents as paraneoplastic tumor-induced osteomalacia. Their diagnosis is often significantly delayed due to their rare occurrence in addition to the generalized and vague symptoms of their presentation including...

Full description

Saved in:
Bibliographic Details
Published in:Radiology case reports 2019-12, Vol.14 (12), p.1518-1524
Main Authors: Richardson, Adam L., Richardson, Olivia K.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3307-a022c9f63d26803cf4acea5f9a5e4c6e646c5970f994fd2e03e3cbceef9ae9713
cites cdi_FETCH-LOGICAL-c3307-a022c9f63d26803cf4acea5f9a5e4c6e646c5970f994fd2e03e3cbceef9ae9713
container_end_page 1524
container_issue 12
container_start_page 1518
container_title Radiology case reports
container_volume 14
creator Richardson, Adam L.
Richardson, Olivia K.
description Phosphaturic mesenchymal tumors (PMT) are an extremely rare pathologic phenomenon that presents as paraneoplastic tumor-induced osteomalacia. Their diagnosis is often significantly delayed due to their rare occurrence in addition to the generalized and vague symptoms of their presentation including progressive bone pain, myopathies, arthralgias, fractures, and generalized weakness. This case report identifies a very characteristic presentation of a 37-year old African American male suffering from a PMT; with symptom onset presenting over 5-years prior to presentation with a consistent complaint of progressive and debilitating quadriparesis. The tumor was first identified by pelvic computerized tomography, although it was initially thought to be a noncontributory benign soft tissue mass. It was only after being hospitalized due to a severe and unresponsive hypophosphatemic state (less than 1 mg/dl) that the collective differential switched to one of a PMT with follow up nuclear 99mTc bone scintigraphy and magnetic resonance imaging being used to aid in the overall assessment of changes, extent, and general metabolic properties of the tumor. The confirmatory diagnosis of a PMT was later established through both serum fibroblast growth factor 23 testing and histopathologic review of the surgically removed specimen. By including this rare but curative disease into the differential of osteomalacia and thereby further examining patient serum phosphate levels, the previous 5-7 year delay in diagnosis will be dramatically reduced.
doi_str_mv 10.1016/j.radcr.2019.09.027
format article
fullrecord <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9fcf9097689641c7834e63b6c8102c32</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9fcf9097689641c7834e63b6c8102c32</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_6818391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3307-a022c9f63d26803cf4acea5f9a5e4c6e646c5970f994fd2e03e3cbceef9ae9713</originalsourceid><addsrcrecordid>eNpVkU1Lw0AQhhdRbK3-Ai-5S-rsTrrJehCk-FEo6EHPy3Yy26YkTdikQv-9aSti4YUZ5uNhmFeIWwljCVLfr8fB5RTGCqQZQy-VnomhNAgxJIjn__KBuGrbNYDGLJWXYoBSZzKZyKG4-1jVbbNy3TYUFFXc8oZWu8qVUbet6vAQTV3LUeCmDt21uPCubPnmN47E18vz5_Qtnr-_zqZP85gQIY0dKEXGa8yVzgDJJ47YTbxxE05Is040TUwK3pjE54oBGWlBzP0Em1TiSMyO3Lx2a9uEonJhZ2tX2EOhDkvrQldQydZ48gZMqjOjE0lphglrXGjKJChC1bMej6xmu6g4J950wZUn0NPOpljZZf1t-wdlaPbH4BFAoW7bwP5vV4Ld-2DX9uCD3ftgoZdK8QdSqnwz</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phosphaturic mesenchymal tumor: Case report</title><source>Elsevier ScienceDirect Journals</source><source>PubMed Central</source><creator>Richardson, Adam L. ; Richardson, Olivia K.</creator><creatorcontrib>Richardson, Adam L. ; Richardson, Olivia K.</creatorcontrib><description>Phosphaturic mesenchymal tumors (PMT) are an extremely rare pathologic phenomenon that presents as paraneoplastic tumor-induced osteomalacia. Their diagnosis is often significantly delayed due to their rare occurrence in addition to the generalized and vague symptoms of their presentation including progressive bone pain, myopathies, arthralgias, fractures, and generalized weakness. This case report identifies a very characteristic presentation of a 37-year old African American male suffering from a PMT; with symptom onset presenting over 5-years prior to presentation with a consistent complaint of progressive and debilitating quadriparesis. The tumor was first identified by pelvic computerized tomography, although it was initially thought to be a noncontributory benign soft tissue mass. It was only after being hospitalized due to a severe and unresponsive hypophosphatemic state (less than 1 mg/dl) that the collective differential switched to one of a PMT with follow up nuclear 99mTc bone scintigraphy and magnetic resonance imaging being used to aid in the overall assessment of changes, extent, and general metabolic properties of the tumor. The confirmatory diagnosis of a PMT was later established through both serum fibroblast growth factor 23 testing and histopathologic review of the surgically removed specimen. By including this rare but curative disease into the differential of osteomalacia and thereby further examining patient serum phosphate levels, the previous 5-7 year delay in diagnosis will be dramatically reduced.</description><identifier>ISSN: 1930-0433</identifier><identifier>EISSN: 1930-0433</identifier><identifier>DOI: 10.1016/j.radcr.2019.09.027</identifier><identifier>PMID: 31681451</identifier><language>eng</language><publisher>Elsevier</publisher><subject>Diagnostic Imaging</subject><ispartof>Radiology case reports, 2019-12, Vol.14 (12), p.1518-1524</ispartof><rights>2019 The Authors 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3307-a022c9f63d26803cf4acea5f9a5e4c6e646c5970f994fd2e03e3cbceef9ae9713</citedby><cites>FETCH-LOGICAL-c3307-a022c9f63d26803cf4acea5f9a5e4c6e646c5970f994fd2e03e3cbceef9ae9713</cites><orcidid>0000-0003-2225-1188 ; 0000-0002-1614-9526</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818391/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818391/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Richardson, Adam L.</creatorcontrib><creatorcontrib>Richardson, Olivia K.</creatorcontrib><title>Phosphaturic mesenchymal tumor: Case report</title><title>Radiology case reports</title><description>Phosphaturic mesenchymal tumors (PMT) are an extremely rare pathologic phenomenon that presents as paraneoplastic tumor-induced osteomalacia. Their diagnosis is often significantly delayed due to their rare occurrence in addition to the generalized and vague symptoms of their presentation including progressive bone pain, myopathies, arthralgias, fractures, and generalized weakness. This case report identifies a very characteristic presentation of a 37-year old African American male suffering from a PMT; with symptom onset presenting over 5-years prior to presentation with a consistent complaint of progressive and debilitating quadriparesis. The tumor was first identified by pelvic computerized tomography, although it was initially thought to be a noncontributory benign soft tissue mass. It was only after being hospitalized due to a severe and unresponsive hypophosphatemic state (less than 1 mg/dl) that the collective differential switched to one of a PMT with follow up nuclear 99mTc bone scintigraphy and magnetic resonance imaging being used to aid in the overall assessment of changes, extent, and general metabolic properties of the tumor. The confirmatory diagnosis of a PMT was later established through both serum fibroblast growth factor 23 testing and histopathologic review of the surgically removed specimen. By including this rare but curative disease into the differential of osteomalacia and thereby further examining patient serum phosphate levels, the previous 5-7 year delay in diagnosis will be dramatically reduced.</description><subject>Diagnostic Imaging</subject><issn>1930-0433</issn><issn>1930-0433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1Lw0AQhhdRbK3-Ai-5S-rsTrrJehCk-FEo6EHPy3Yy26YkTdikQv-9aSti4YUZ5uNhmFeIWwljCVLfr8fB5RTGCqQZQy-VnomhNAgxJIjn__KBuGrbNYDGLJWXYoBSZzKZyKG4-1jVbbNy3TYUFFXc8oZWu8qVUbet6vAQTV3LUeCmDt21uPCubPnmN47E18vz5_Qtnr-_zqZP85gQIY0dKEXGa8yVzgDJJ47YTbxxE05Is040TUwK3pjE54oBGWlBzP0Em1TiSMyO3Lx2a9uEonJhZ2tX2EOhDkvrQldQydZ48gZMqjOjE0lphglrXGjKJChC1bMej6xmu6g4J950wZUn0NPOpljZZf1t-wdlaPbH4BFAoW7bwP5vV4Ld-2DX9uCD3ftgoZdK8QdSqnwz</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Richardson, Adam L.</creator><creator>Richardson, Olivia K.</creator><general>Elsevier</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2225-1188</orcidid><orcidid>https://orcid.org/0000-0002-1614-9526</orcidid></search><sort><creationdate>20191201</creationdate><title>Phosphaturic mesenchymal tumor: Case report</title><author>Richardson, Adam L. ; Richardson, Olivia K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3307-a022c9f63d26803cf4acea5f9a5e4c6e646c5970f994fd2e03e3cbceef9ae9713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Diagnostic Imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Richardson, Adam L.</creatorcontrib><creatorcontrib>Richardson, Olivia K.</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Radiology case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Richardson, Adam L.</au><au>Richardson, Olivia K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phosphaturic mesenchymal tumor: Case report</atitle><jtitle>Radiology case reports</jtitle><date>2019-12-01</date><risdate>2019</risdate><volume>14</volume><issue>12</issue><spage>1518</spage><epage>1524</epage><pages>1518-1524</pages><issn>1930-0433</issn><eissn>1930-0433</eissn><abstract>Phosphaturic mesenchymal tumors (PMT) are an extremely rare pathologic phenomenon that presents as paraneoplastic tumor-induced osteomalacia. Their diagnosis is often significantly delayed due to their rare occurrence in addition to the generalized and vague symptoms of their presentation including progressive bone pain, myopathies, arthralgias, fractures, and generalized weakness. This case report identifies a very characteristic presentation of a 37-year old African American male suffering from a PMT; with symptom onset presenting over 5-years prior to presentation with a consistent complaint of progressive and debilitating quadriparesis. The tumor was first identified by pelvic computerized tomography, although it was initially thought to be a noncontributory benign soft tissue mass. It was only after being hospitalized due to a severe and unresponsive hypophosphatemic state (less than 1 mg/dl) that the collective differential switched to one of a PMT with follow up nuclear 99mTc bone scintigraphy and magnetic resonance imaging being used to aid in the overall assessment of changes, extent, and general metabolic properties of the tumor. The confirmatory diagnosis of a PMT was later established through both serum fibroblast growth factor 23 testing and histopathologic review of the surgically removed specimen. By including this rare but curative disease into the differential of osteomalacia and thereby further examining patient serum phosphate levels, the previous 5-7 year delay in diagnosis will be dramatically reduced.</abstract><pub>Elsevier</pub><pmid>31681451</pmid><doi>10.1016/j.radcr.2019.09.027</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2225-1188</orcidid><orcidid>https://orcid.org/0000-0002-1614-9526</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1930-0433
ispartof Radiology case reports, 2019-12, Vol.14 (12), p.1518-1524
issn 1930-0433
1930-0433
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_9fcf9097689641c7834e63b6c8102c32
source Elsevier ScienceDirect Journals; PubMed Central
subjects Diagnostic Imaging
title Phosphaturic mesenchymal tumor: Case report
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T20%3A14%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phosphaturic%20mesenchymal%20tumor:%20Case%20report&rft.jtitle=Radiology%20case%20reports&rft.au=Richardson,%20Adam%20L.&rft.date=2019-12-01&rft.volume=14&rft.issue=12&rft.spage=1518&rft.epage=1524&rft.pages=1518-1524&rft.issn=1930-0433&rft.eissn=1930-0433&rft_id=info:doi/10.1016/j.radcr.2019.09.027&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_6818391%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3307-a022c9f63d26803cf4acea5f9a5e4c6e646c5970f994fd2e03e3cbceef9ae9713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/31681451&rfr_iscdi=true